Aeglea Nosedives After Update On Rare Metabolism Disease Candidate

 

• Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 trial of pegtarviliase in Classical Homocystinuria in the fourth quarter of 2022. 
• Enrollment in the third cohort of the Phase 1/2 trial is ongoing, with two patients having completed dosing in the cohort.
• In October, the FDA placed a partial clinical hold for enrolling patients under 18 years of age under the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria Investigational New Drug (IND). 
• Additionally, the company has decided not to participate in the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.
• Aeglea looks forward to delivering a clinical update on the pegtarviliase program when more comprehensive data from the third cohort becomes available.

https://www.benzinga.com/general/biotech/22/11/29907443/aeglea-shares-nosedives-after-clinical-update-on-investigational-candidate-for-rare-metabolism-di